Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer:: current evidence
-
I. García Escobar [1] ; E. Brozos Vázquez [6] ; D. Gutierrez Abad [2] ; V. Martínez Marín [3] ; V. Pachón [4] ; A. J. Muñoz Martín [5]
-
[1] Hospital General de Ciudad Real
Hospital General de Ciudad Real
Ciudad Real, España
-
[2] Hospital de Fuenlabrada
Hospital de Fuenlabrada
Fuenlabrada, España
-
[3] Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, España
-
[4] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[5] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[6] Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 6, 2021, págs. 1034-1046
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as efective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efcacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efcacy and safety and the limited information in patients with cancer; in addition, we will briefy review their pharmacokinetic properties with special reference to potential interactions.
